Back to results
US 11,530,208 B2Granted
Imidazo[4,5-C]pyridine derived SSAO inhibitors
AssigneeProximagen Limited
InventorsLee Patient, Iain Simpson, Edward Savory
Life of this patent
Estimating the term…
Abstract
A compound of formula (I) or a pharmaceutically acceptable salt, or N-oxide thereof and the use of the same in therapy: wherein Z, Y, R1, W, V, and R3 are as defined in claim 1.
Claims16
A compound of formula (I) or a pharmaceutically acceptable salt, or N-oxide thereof:
- wherein Y is selected from hydrogen, hydroxyl, —NH2, —NH—C1-4-alkyl, —NH-halo-C1-4-alkyl, or —C1-4-alkoxy;
- wherein Z is selected from hydrogen, halogen, hydroxyl, cyano, C1-4-alkyl, halo-C1-4-alkyl, C1-4-alkoxy, halo-C1-4-alkoxy, —CONH2, —SO2NH2, —NH2, —NHC1-4-alkyl, and —NH-halo-C1-4-alkyl;
- wherein R1 is a phenyl ring, or a 5 or 6-membered heteroaryl ring, either ring optionally substituted with one or more substituents selected from halogen, cyano, C1-4-alkyl, halo-C1-4-alkyl, cyano-C1-4-alkyl, —OR5, NR4AR4B, —NR6C(O)OR5, —NR6C(O)R5, —NR6C(O)NR4AR4B, —C(O)NR4AR4B, —C(O)R5, —C(O)OR5, and —NR6S(O)2R5;
- wherein R4A, R4B, R5, and R6 are each independently selected from hydrogen, C1-4-alkyl and halo-C1-4-alkyl, or
- wherein each of R4A and R4B, together with the nitrogen to which they are attached, form a 3-7 membered cyclic amino group, optionally substituted by one or more substituents selected from:
- halogen, hydroxyl, cyano, C1-4-alkyl, halo-C1-4-alkyl, C1-4-alkoxy, halo-C1-4-alkoxy, —CONH2, —SO2NH2, —NH2, —NHC1-4-alkyl, and —NH-halo-C1-4-alkyl;
- wherein W is a [6,5] heteroaryl ring system formed by fusing together phenyl and pyrrolidinyl or imidazolyl and wherein either ring is optionally substituted with one or more groups selected from halogen, oxo, hydroxyl, cyano, C1-4-alkyl, halo-C1-4-alkyl, cyano-C1-4-alkyl, —OR5, —NR4AR4B, —NR6C(O)OR5, —NR6C(O)R5, —NR6C(O)NR4AR4B, —C(O)NR4AR4B, —C(O)R5, —C(O)OR5, —SO2R5, —SO2NR4AR4B, and —NR6S(O)2R5;
- wherein V is a direct bond;
- and
- wherein R3 is hydrogen.
7 more elements
A compound of formula (I) or a pharmaceutically acceptable salt, or N-oxide thereof:
- wherein Y is selected from hydrogen, hydroxyl, —NH2, —NH—C1-4-alkyl, —NH-halo-C1-4-alkyl, and —C1-4-alkoxy;
- wherein Z is selected from hydrogen, halogen, hydroxyl, cyano, C1-4-alkyl, halo-C1-4-alkyl, C1-4-alkoxy, halo-C1-4-alkoxy, —CONH2, —SO2NH2, —NH2, —NHC1-4-alkyl, and —NH-halo-C1-4-alkyl;
- wherein R1 is a phenyl ring, or a 5 or 6-membered heteroaryl ring, either ring optionally substituted with one or more substituents selected from halogen, cyano, C1-4-alkyl, halo-C1-4-alkyl, cyano-C1-4-alkyl, —OR5, —NR4AR4B, —NR6C(O)OR5, —NR6C(O)R5, —NR6C(O)NR4AR4B, —C(O)NR4AR4B, —C(O)R5, —C(O)OR5, and —NR6S(O)2R5;
- wherein R4A, R4B, R5, and R6 are each independently selected from hydrogen, C1-4-alkyl and halo-C1-4-alkyl, or
- wherein each of R4A and R4B, together with the nitrogen to which they are attached, form a 3-7 membered cyclic amino group, optionally substituted by one or more substituents selected from:
- halogen, hydroxyl, cyano, C1-4-alkyl, halo-C1-4-alkyl, C1-4-alkoxy, halo-C1-4-alkoxy, —CONH2, —SO2NH2, —NH2, —NHC1-4-alkyl, and —NH-halo-C1-4-alkyl;
- wherein W is a 5 or 6-membered heterocyclic ring optionally substituted with one or more substituents selected from halogen, oxo, hydroxyl, cyano, C1-4-alkyl, halo-C1-4-alkyl, cyano-C1-4-alkyl, —OR5, —NR4AR4B, —NR6C(O)OR5, —NR6C(O)R5, —NR6C(O)NR4AR4B, —C(O)NR4AR4B, —C(O)R5, —C(O)OR5, —SO2R5, —SO2NR4AR4B, and —NR6S(O)2R5;
- wherein V is a direct bond;
- and
- wherein R3 is a phenyl ring or a 5 or 6-membered heteroaryl ring optionally substituted with one or more substituents selected from halogen, oxo, hydroxyl, cyano, C1-4-alkyl, halo-C1-4-alkyl, cyano-C1-4-alkyl, —OR5, —NR4AR4B, —NR6C(O)OR5, —NR6C(O)R5, —NR6C(O)NR4AR4B, —C(O)NR4AR4B, —C(O)R5, —C(O)OR5, —SO2R5, —SO2NR4AR4B and —NR6S(O)2R5.
7 more elements
Dependencies are inferred from the claim text.